Evidence map›Paper›PMID 27912784›Full record

Trial reportCardiovascular diabetology2016

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study.

Manfredi Rizzo, Ali A Rizvi, Angelo Maria Patti, Dragana Nikolic, Rosaria Vincenza Giglio, Giuseppa Castellino, Giovanni Li Volti, Massimiliano Caprio, Giuseppe Montalto, Vincenzo Provenzano and 2 more

2 registry-linked trialsOpen access · goldFull text readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cardiovascular diabetology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 66 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 3 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03377335 phase4unknown statusstarted 2017, after this paper: background citation

Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes

Ran2017Enrolled186Registered outcomes6Posted comparisons0ConditionsType 2 Diabetes MellitusArmsDapagliflozin 10mg, Metformin
PMID 26864445PMID 24559258PMID 25393640PMID 24349318PMID 22197629PMID 21595628PMID 20525999PMID 18418229PMID 26114349PMID 26493719PMID 26980776other papers from this trial
Open the trial in the graph
NCT01715428 completednot on this map

Effects of Liraglutide on Cardio-Metabolic Risk Markers

TypeobservationalSponsorUniversity of PalermoRan2012 to 2015Enrolled300ConditionsType-2 Diabetes
3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. AltilixNutrients · 2019
    Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

Manfredi RizzoBiomedical Dept of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Ali A RizviDivision of Endocrinology, Diabetes and Metabolism, University of South Carolina School of Medicine, Columbia, SC, USA.
Angelo Maria PattiBiomedical Dept of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Dragana NikolicBiomedical Dept of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy. draggana.nikolic@gmail.com.ORCID http://orcid.org/0000-0001-9572-9651
Rosaria Vincenza GiglioBiomedical Dept of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Giuseppa CastellinoBiomedical Dept of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Giovanni Li VoltiDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Massimiliano CaprioLaboratory of Cardiovascular Endocrinology, IRCCS San Raffaele Pisana, Rome, Italy.
Giuseppe MontaltoBiomedical Dept of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Vincenzo ProvenzanoDepartment of Internal Medicine, Regional Center for Diabetology, Partinico Hospital, Partinico, Italy.
Stefano GenoveseIRCCS MultiMedica, Milan, Italy.
Antonio CerielloIRCCS MultiMedica, Milan, Italy.
University of Palermo · ITUniversity of South Carolina · USCentro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas · ESIRCCS Ospedale San Raffaele · ITIstituto di Biomedicina e di Immunologia Molecolare Alberto Monroy · ITMultiMedica · ITUniversity of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLiraglutide, a GLP-1 analogue, exerts several beneficial non-glycemic effects in patients with type-2 diabetes (T2DM), such as those on body weight, blood pressure, plasma lipids and inflammation markers. However, the effects of liraglutide on cardiovascular (CV) risk markers in subjects with the metabolic syndrome (MetS) are still largely unknown. We herein explored its effects on various cardio-metabolic risk markers of the MetS in subjects with T2DM.

methodsWe performed an 18-month prospective, real-world study. All subjects had T2DM and the MetS based on the AHA/NHLBI criteria. Subjects with a history of a major CV event were excluded. One hundred-twenty-one subjects (71 men and 50 women; mean age: 62 ± 9 years) with T2DM and the MetS, who were naïve to incretin-based therapies and treated with metformin only, were included. Liraglutide (1.2 mg/day) was added to metformin (1500-3000 mg/day) for the entire study. Fasting plasma samples for metabolic parameters were collected and carotid-intima media thickness (cIMT) was assessed by B-mode real-time ultrasound at baseline and every 6 months thereafter.

resultsThere was a significant reduction in waist circumference, body mass index, fasting glycemia, HbA1c, total- and LDL-cholesterol, triglycerides, and cIMT during the 18-month follow-up. Correlation analysis showed a significant association between changes in cIMT and triglycerides (r = 0.362; p < 0.0001). The MetS prevalence significantly reduced during the study, and the 26% of subjects no longer fulfilled the criteria for the MetS after 18 months.

conclusionsLiraglutide improves cardio-metabolic risk factors in subjects with the MetS in a real-world study. Trial Registration ClinicalTrials.gov: NCT01715428.

Indexed as

Carotid Intima-Media ThicknessAgedBiomarkersCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEchocardiography, Doppler, ColorFemaleHumansHypoglycemic AgentsIncretinsItalyLiraglutideMaleMetabolic SyndromeMetforminBiomarkersHypoglycemic AgentsIncretinsLiraglutideMetforminCardiovascular riskCarotid intima-media thicknessLiraglutideMetabolic syndrome

Identifiers

PMID27912784
PMCPMC5135832
OpenAlexW2558288750

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.